Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: Preparation of a genetically engineered anti-CEa single chain Fv antibody

被引：11

作者：

Mayer, A ^{[1
]}

Chester, KA ^{[1
]}

Bhatia, J ^{[1
]}

Pedley, RB ^{[1
]}

Read, DA ^{[1
]}

Boxer, GM ^{[1
]}

Begent, RHJ ^{[1
]}

机构：

[1] Royal Free Hosp, Sch Med, Dept Clin Oncol, Canc Res Campaign Targeting & Imaging Grp, London NW3 2PF, England

来源：

EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷 / 07期

关键词：

quality; safety; control recommendations; biotechnology; single chain Fv;

D O I：

10.1016/S0959-8049(98)00035-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Products of recombinant DNA technology have potential for the diagnosis or treatment of cancer. There is a need to investigate whether they function by the intended mechanism in small phase I clinical trials before their suitability for more extensive studies can be assessed. Quality and safety of these products should be assured prior to their use in humans in a way which is appropriate to the preliminary nature of the trials but not inhibitory to progress. The Cancer Research Campaign control recommendations for products derived from recombinant DNA technology (Begent RHJ and associates. EurJ Cancer 1993, 29A, 13, 1907-1910) provide guidelines for the production of new biotechnology products in academic research units within a relatively short time, while ensuring appropriate quality and safety. The practical application of the guidelines requires that solutions are found for the quality and safety issues during the production of recombinant products. We describe an approach to the relevant quality and safety issues during and after the production and purification of a genetically engineered anti-carcinoembryonic antigen (CEA) single chain Fv (scFv) antibody for a phase I trial of radioimmunoguided surgery with the intention of providing a model for other products. (C) 1998 Elsevier Science Ltd. All rights reserved.

引用

页码：968 / 976

页数：9

共 13 条

[1]

[Anonymous], ICRP PUBL

[2]

ARRIGO C, 1992, EUR J CANCER, V28A, P1289

[3]

BEGENT RHJ, 1986, BRIT J CANCER, V54, P557

[4] CANCER-RESEARCH CAMPAIGN OPERATION MANUAL FOR CONTROL RECOMMENDATIONS FOR PRODUCTS DERIVED FROM RECOMBINANT-DNA TECHNOLOGY PREPARED FOR INVESTIGATIONAL ADMINISTRATION TO PATIENTS WITH CANCER IN PHASE-I TRIALS [J].

BEGENT, RHJ ;

CHESTER, KA ;

CONNORS, T ;

CROWTHER, D ;

FOX, B ;

GRIFFITHS, E ;

HINCE, TA ;

LEDERMANN, JA ;

MCVIE, JG ;

MINOR, P ;

SECHER, DS ;

SCHWARTSMANN, G ;

THORPE, R ;

WILBIN, C ;

ZWIERZINA, H .

EUROPEAN JOURNAL OF CANCER, 1993, 29A (13) :1907-1910

[5] Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library [J].

Begent, RHJ ;

Verhaar, MJ ;

Chester, KA ;

Casey, JL ;

Green, AJ ;

Napier, MP ;

HopeStone, LD ;

Cushen, N ;

Keep, PA ;

Johnson, CJ ;

Hawkins, RE ;

Hilson, AJW ;

Robson, L .

NATURE MEDICINE, 1996, 2 (09) :979-984

[6] PROTEIN-PURIFICATION - ASPECTS OF PROCESSES FOR PHARMACEUTICAL PRODUCTS [J].

BERTHOLD, W ;

WALTER, J .

BIOLOGICALS, 1994, 22 (02) :135-150

[7] PURIFICATION OF BACTERIALLY EXPRESSED SINGLE-CHAIN FV ANTIBODIES FOR CLINICAL-APPLICATIONS USING METAL CHELATE CHROMATOGRAPHY [J].

CASEY, JL ;

KEEP, PA ;

CHESTER, KA ;

ROBSON, L ;

HAWKINS, RE ;

BEGENT, RHJ .

JOURNAL OF IMMUNOLOGICAL METHODS, 1995, 179 (01) :105-116

[8] PHAGE LIBRARIES FOR GENERATION OF CLINICALLY USEFUL ANTIBODIES [J].

CHESTER, KA ;

BEGENT, RHJ ;

ROBSON, L ;

KEEP, P ;

PEDLEY, RB ;

BODEN, JA ;

BOXER, G ;

GREEN, A ;

WINTER, G ;

COCHET, O ;

HAWKINS, RE .

LANCET, 1994, 343 (8895) :455-456

[9] RADIOIMMUNOTHERAPY OF METASTATIC COLORECTAL TUMORS WITH IODINE-131-LABELED ANTIBODY TO CARCINOEMBRYONIC ANTIGEN - PHASE I/II STUDY WITH COMPARATIVE BIODISTRIBUTION OF INTACT AND F(AB')(2) ANTIBODIES [J].

LANE, DM ;

EAGLE, KF ;

BEGENT, RHJ ;

HOPESTONE, LD ;

GREEN, AJ ;

CASEY, JL ;

KEEP, PA ;

KELLY, AMB ;

LEDERMANN, JA ;

GLASER, MG ;

HILSON, AJW .

BRITISH JOURNAL OF CANCER, 1994, 70 (03) :521-525

[10]

Loevinger R., 1991, MIRD PRIMER ABSORBED

← 1 2 →